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The secretion of reactive oxygen intermediates is one  means by which  leukocytes 
can  lyse tumor cells without  phagocytosis (1-9).  We have  identified two settings in 
which  macrophages  make  use  of  this  mechanism:  when  the  respiratory  burst  is 
triggered by pharmacologic agents  (5,  6)  or by anti-tumor antibody  (7,  8).  In  both 
cases,  activated macrophages,  which  can  secrete  abundant  hydrogen  peroxide  (10, 
11),  destroy  tumor  cells.  Resident  peritoneal  macrophages  or  those  elicited  with 
certain sterile inflammatory agents secrete little H202  (10,  11)  and are not cytolytic 
(5,  7). 
Tumor  cells  vary  widely  in  their  susceptibility to  lysis  by  H202  (5,  12)  or  by 
peroxide-producing leukocytes (5). However, little is known about anti-oxidant defen- 
ses of tumor  cells, which  might  affect  their susceptibility or resistance to  oxidative 
injury. 
In this report, we studied six murine tumors differeing >50-fold in their suscepti- 
bility to  lysis by enzymatically generated  H202.  We measured  the activities of two 
peroxide-catabolizing pathways:  catalase and  the cyclic oxidation and  reduction of 
glutathione.  We  inhibited  both  pathways,  and  observed  the  effects  on  lysis of the 
tumors by fluxes of H202  and by macrophages in the presence of phorbol myristate 
acetate  (PMA) a  or  anti-tumor  antibody.  The  results  suggest  that  the  tumor  cell 
glutathione  cycle  can  be  a  rate-limiting  factor  in  cytotoxicity.  Inhibition  of this 
pathway  makes  tumor  cells  more  susceptible  to  macrophage-mediated  oxidative 
injury. 
* Supported by grant CA-22090 from the National Cancer Institute. 
:~ Scholar of the Leukemia Society of America and Irma T. Hirshl Career Scientist. 
§ Recipient of the Andrew W. Mellon Foundation Teacher-Scientist Award. 
1Abbreviations used in  this paper: Ara-C,  cytosine-l-fl-D-arabinofuranoside hydrochloride;  BCG, bacille 
Calmette-Gu~rin;  BCNU,  1,3-bis(2-chloroethyl)-  l-nitrosourea;  CCNU,  1-(2-chloroethyl)-3-(cyclohexyl)-  1- 
nitrosourea;  FBS,  fetal  bovine  serum  heated  at  56°C  for  30  rain;  y-GCS,  gamma-glutamylcysteine 
synthetase;  GPO, glutathione peroxidase; GR, glutathione  reductase; GS, glutathione synthetase; GSH, 
reduced glutathione; GSSG, glutathione disulfide; GST, glutathione S-transferase; HS, horse serum heated 
at 56°C for 30 min; IDs0, dose causing 50% inhibition;  LDs0, dose lethal to 50% of cells; MEM, Eagle's 
minimum essential medium, alpha variant; methyl-CCNU,  l-(2-chloroethyl)-3-(4-transmethylcyclohexyl)- 
1-nitrosourea; PBS, Dulbecco's phosphate-buffered  saline; PMA, phorbol  myristate acetate;  RPMI-10% 
FBS, RPMI supplemented  with  100/~g/ml streptomycin,  100 U/ml penicillin, 300/.tg/ml  glutamine, 0.1 
mM nonessential amino acids,  1 mM sodium pyruvate,  5 ×  10  -~ M 2-mercaptoethanol,  and  10% heat- 
inactivated  FBS. 
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Materials  and  Methods 
Tumors.  J774  cells were maintained in spinner culture, and were the kind gift of Ms H. 
Plutner,  Dr. J.  Unkeless, and  Dr.  I.  Mellman, The  Rockefeller University, New  York.  The 
other tumors were used either as ascites or as stationary suspension cultures in Eagle's minimum 
essential medium (alpha variant) (MEM), supplemented with 100/~g/ml streptomycin, 100 U/ 
ml penicillin, and 5-10% heat-inactivated horse serum (HS) (Flow Laboratories, Inc., Rockville, 
Md.). P388 lymphoma cells were passed in  (BALB/c ×  DBA/2)F1  (CD2F1) mice (Simonsen 
Laboratories, Gilroy, Calif.), TLX9 and NK lymphomas in C57BL/6 mice (Simonsen Labo- 
ratories; The Jackson Laboratory, Bar Harbor, Maine; or Trudeau Institute, Saranac Lake, N. 
Y.), and YAC-1 lymphoma in A strain mice (The Jackson Laboratory, or Trudeau Institute). 
NK lymphoma, which arose in a C3 strain mouse around 1959 (13), was obtained through the 
courtesy of Dr. J. Mayo, Division of Cancer Treatment, National Cancer Institute, Frederick 
Cancer  Research  Center,  Frederick, Md.,  from  a  Hungarian  stock.  The other tumors were 
obtained as described (5, 7). 
Diet.  For most studies, mice were fed ad libitum with rodent laboratory chow 5001  (Ralston 
Purina Co., St. Louis, Mo.) and tap water. Where indicated, the mice were fed a  selenium- 
deficient diet according to the formulation ofRotruck et al. (14) supplemented with 100 IU/kg 
tocopherol acetate (ICN Nutritional Biochemicals, Cleveland, Ohio). As a control, littermates 
were fed the same diet repleted with  1 ppm sodium selenite, to which was added 0.05%  by 
weight of a  mixture of FD & C  red dye No.  2,  yellow No.  5,  and  blue No.  1 as an  aid in 
identification. The special diets were stored at -20 °  C  to retard spoilage. Mice receiving the 
special diets were only given deionized water double-distilled in glass. They gained weight at 
the same rate as littermates receiving chow 5001.  Tumors grew in all three groups of mice at 
the same rate. 
Effector Cells.  Peritoneal cells were obtained from untreated CD2F1 female mice (resident 
cells); 10-42 d  after intraperitoneal injection of viable bacille Calmette-Gu~rin (BCG)  (BCG 
cells); 4-5 d after intraperitoneal injection of thioglycollate broth (thioglycollate cells); or 12- 
18 h  after thioglyeollate broth (granulocytes). Details of the elieitation, collection, hypotonic 
lysis, and differential counting of these populations have been presented elsewhere (5,  7,  10). 
Effector:target ratios are reported  on  the basis of the  proportion of macrophages detected 
among the resident, BCG, or thioglycollate  cells, or the granulocytes in the acute thioglycollate- 
broth exudates, as described elsewhere (10). To prepare cytolytic T  cells, C57BL/6 and CD2F1 
mice were injected intraperitoneally with spleen cells of the opposite strain. 25-32 wk later, 
spleens were pressed through a 40-gauge wire screen with glass stoppers, and washed in RPMI- 
1640 supplemented with  100/~g/ml streptomycin, 100 U/ml penicillin, 300 p.g/ml glutamine, 
0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 5 ×  10-SM 2-mercaptoethanol, and 
10% heat-inactivated fetal bovine serum (RPMI-10%FBS) (Flow Laboratories, Inc.). Erythro- 
cytes were lysed with 1.6% ammonium chloride. 7 ×  106 responder cells were incubated with 4 
×  106 irradiated (2,000  rad) stimulator cells in 2 ml RPMI-10%FBS in  16-mm wells (Costar, 
Data Packaging, Cambridge, Mass.) for 5 d. The cells were washed and replated at 4 ×  106/ 
well with  1 ×  106 fresh, irradiated stimulator cells. Effector cells were collected 2-5 d later. 
Use  of Pharmacologic Agents.  The  following  preservative-free  compounds  were  obtained 
through the courtesy of Dr. V. L. Narayanan, Drug Synthesis and Chemistry Branch, and Dr. 
J.  D.  Douros,  Natural  Products  Branch,  Developmental Therapeutics Program,  Division of 
Cancer Treatment, National Cancer Institute, Bethesda, Md.: 1,3-bis (2-chloroethyl)-  1-nitrosou- 
rea  (BCNU;  NSC  409962);  1-(2-chloroethyl)-3-(4-transmethylcyclohexyl)-l-nitrosourea 
(methyl-CCNU;  NSC  95441);  1-(2-chloroethyl)-3-(cyclohexyl)-l-nitrosourea (CCNU;  NSC 
79037):  cis-diaminedichloroplatinum (NSC  119875);  and  doxorubicin hydrochloride  (NSC 
123127). The following were from Sigma Chemical Co., St. Louis, Mo.: mitomyein C, cytosine- 
1-fl-D-arabinofuranoside hydrochloride (Ara-C), 2-amino-6-mercaptopurine (6-thioguanine), 5- 
fluorouracil, 4-(bis[2-chloroethyl]amino)-L-phenylalanine (melphalan), 3-amino-l,2,4-triazole, 
chlorambucil, and  catalase  (thymol-free). Cyclophosphamide monohydrate was  a  gift  from 
Mead Johnson & Co., Evansville, Ill. Methotrexate was from Lederle Laboratories, Pearl River, 
N.Y. 
Tumor cells were labeled with  5~  Na2 [  Cr]O4 as described before (5), washed by centrifugation, 
resuspended in MEM-I% HS, and divided into two aliquots of 5 ×  106-1 ×  107 cells in 1 ml or 768  TUMOR CELL ANTI-OXIDANT DEFENSES 
1 ×  107-2  ×  10  7 cells in  2  ml.  Each  tube  then  received 0.1  or 0.2  ml of vehicle (MEM-I% 
ethanol)  (final ethanol concentration, 0.09%), or an equal volume of vehicle that contained  1.1 
mg/ml BCNU (final concentration:  100/~g/ml or 0.467 mM). After 10 min at 37°C, the tumor 
cells were washed once in MEM-I% HS and twice in MEM-5% HS. The BCNU was stored at 
-20°C, weighed out  immediately before use, dissolved in cold absolute ethanol,  and diluted 
with cold, serum-free MEM before addition to the tumor cells. During the above procedures, 
the pH of the medium was maintained  no higher than  7.3 by gassing with 5% CO2/95% air. 
Careful control  of the pH and  serum concentration  was  necessary  to avoid toxicity (15-18). 
Other drugs  were also used at 0.467  mM for  10-30  min exposures,  except  for aminotriazole. 
The latter was present  at  25-50  mM during the 45-60  min period of 51Cr-labeling, and  was 
also present throughout  the cytolysis assays at 25-50 raM. 
Cytolysis Assays.  To determine susceptibility to lysis by H202,  4  ×  104 51Cr-labeled tumor 
cells in  0.2  ml  MEM-5%  HS  were  added  to  round-bottomed  microtest  plate  wells  (Linbro 
Division, Flow Laboratories, Inc., Hamden, Conn.) which contained 0.02 ml of glucose oxidase 
(Type V, Sigma Chemical Co.) diluted in normal saline. The plates were incubated at 37°C in 
5% CO2/95%  air for 4.5  h,  then centrifuged at  550 g  for 5  min. 0.1  ml of the supernate  was 
removed for  gamma  counting.  In  some experiments,  the wells were made  to contain  0.27% 
trypan  blue,  and  the  ability  of  the  tumor  cells  to  exclude  the  dye  was  observed  in  a 
hemocytometer. For experiments with J774 and NK lymphoma cells, in which high concentra- 
tions of glucose oxidase were employed, the glucose concentration of the medium was increased 
to 44  mM.  To test  cell-mediated cytotoxicity, various numbers  of effector cells and  2  ×  104 
51Cr-labeled tumor cells were added  to the wells in a  total  vol of 0.2 ml of MEM-5%, either 
alone, or in the presence of 100  ng/ml PMA, 0.0033%  dimethylsulfoxide, anti-tumor alloanti- 
serum, or nonimmune alloserum, as described (7). In some experiments with selenium-deficient 
tumor cells, Neuman-Tytell medium  (Grand Island Biological Co., Grand  Island,  N. Y.)  was 
used with 0.25 mg/ml bovine serum albumin. The plates were usually centrifuged at  160 g for 
1 rain, then incubated 4.5 h, before harvest as above. To test antibody-mediated, complement- 
dependent  lysis, 4  ×  104 51Cr-labeled tumor cells in 0.2 ml MEM-5% HS were added  to wells 
with  0.05  ml  of various  dilutions  of heat-inactivated  rabbit  anti-mouse  lymphocyte  serum 
(Microbiological Associates, Walkersville, Md.)  and  0.05  ml absorbed,  screened,  fresh-frozen 
rabbit  serum  (Pel-Freez, Rogers, Ariz.). The supernate  was sampled  3.5  h  later.  The percent 
specific release was calculated as before, reporting the mean and simple proportional SEM for 
triplicates (5). 
Biochemical Assays.  The activity of glucose oxidase was measured with the scopoletin assay 
for H202 (10)  in Krebs-Ringer phosphate buffer, pH 7.35-7.41,  at 37°C in air, with either 5.5 
or 40  mM glucose. These conditions were chosen  to mimic those in the cytolysis assay,  even 
though  they are suboptimal  for the enzyme in terms of the concentrations of glucose, oxygen, 
and hydrogen ion. To measure glutathione reductase  (GR), 5  ×  106-2  ×  10  v nonradiolabeled 
tumor cells were treated with BCNU or with vehicle as described above, washed three times in 
ice-cold  Dulbeceo's  phosphate-buffered  saline  (PBS)  (Grand  Island  Biological Co.)  by  30-s 
centrifugations in a  microfuge (Beckman Instruments  Inc., Spinco Div., Palo Alto, Calif.) and 
resuspended to 1 ml in PBS. They were made 0.2% in Triton X-100 (Sigma Chemical Co.) and 
centrifuged for  10 min. Aliquots of the supernate  were removed for protein determination  by 
the method of Lowry et al.  (19)  using a  bovine serum albumin standard.  0.1-ml aliquots were 
used to measure GR by the method of Roos et al.  (20).  Preliminary experiments showed that 
the activity of GR was not affected by preincubating  the tumor cells for 45  min in Na2CrO4 
(21) at the concentrations used to radiolabel the cells for cytolysis assays. Glutathione peroxidase 
(GPO) was measured in the same lysate supernate by the method of Paglia and Valentine (22). 
Values were  the same using cumene  hydroperoxide  (Polyseiences,  Inc., Warrington,  Pa.)  as 
substrate  rather  than  H202.  Catalase  was  measured  according  to  Baudhuin  et  al.  (23). 
Glutatbione  was  measured  in acid-soluble extracts  of triton  lysates by a  modification of the 
method of Tietze (24)  as described in detail elsewhere (B. A. Arrick, C. F. Nathan,  Z. A. Cohn, 
and O. W. Griffith, manuscript  in preparation).  The total of reduced plus oxidized glutathione 
is expressed as nanomoles of the tripeptide per milligram cell protein. NATHAN, ARRICK, MURRAY, DESANTIS, AND COHN  769 
Results 
Levels  of Catalase,  GPO  GR,  and  Glutathione in  Tumor Cells.  Four  lymphomas,  a 
mastocytoma, and a histiocytoma were chosen for study, because they spanned a 54- 
fold range in susceptibility  to lysis by ~:he H202-generating enzyme, glucose oxidase 
(Table I). At every concentration of glucose oxidase employed, lysis was abolished by 
catalase  (not shown).  The  six  tumors  differed  56.7-fold  in  their  specific  activity  of 
catalase,  5.3-fold in GPO,  and 3.3-fold in GR.  However,  the levels of these enzymes 
did not correlate with the resistance of the tumors to H202.  In contrast, the specific 
cellular content of glutathione correlated with the logarithm of the flux of peroxide 
causing 50% lysis (r -- 0.91). 
Inhibition of Tumor Cell GR by BCNU.  To investigate the contribution of glutathione 
to tumor cell  anti-oxidant defense,  we sought means of inhibiting the enzymes that 
catalyze its oxidation and reduction. The alkylating and carbamoylating agent BCNU 
was recently reported to inhibit GR in human erythrocytes without influencing the 
TABLE  I 
Levels of Anti-Oxidant Defenses and Susceptibility to Lysis by H202 
Tumor  LD~*  Protein:~  Catala.se§  GPOII  GR[[  Glutathione¶ 
TLX9  0.28 ±  0.02 (4)**  56,6 ±  6.1  (8)  14.6 ±  1.7 (7)  87.5 ±  129 (7)  30.4 ±  3.g (6)  17.2 ±  3.7 (5) 
P388  0.3i ~:0.06 (7)  61.i ±  I0.6 (6)  68.7±  13.5 ~5)  243.8±52.I  (3)  22.7 ±  4.6 (6)  II.8~  1.2(6) 
YAC  0.54 ±  0.12 (3)  72.0 4- 6.7 (3)  47.2 ±  14.3 (4)  75,0 :tz 14.9 (3)  36.3 :t: 2,0 (4)  22.4 ±  5.1  (5) 
P815  1.31 ±  0.15 (19)  102.2±9.8(9)  31,5 +  6,6 (4)  174.4±29.6(7)  18.4 ±  1.4 (27)  25.3 ±  2.7 (41 
J774  3.39 ±  2.11 (2)  117.3±6.5(3)  238.0±14,0(4)  54D ±  4.7 (3)  60.4±3.3(4)  277±68(4) 
NK  15.04±0.52(2)  870±  11,3(6)  4.2±2.4(3)  288.3±541  (3)  21.1  ±0.5(3)  31.3±21  (3) 
Ratio, 
highest: 
lowest 
53.7  21  56.7  5.3  3.3  2.7 
* Activity of glucose oxida~e  (nmol H20~/min)  required  to cause 50% specific  release  of SlCr under the standard  conditions  (Materials  and 
Methods). 
~: ug/lO  s cells. 
§ Baudhuin units X  104/mg protein, 
I[ nmol NADPH/min  per mg protein  at room  temperature. 
¶ nmol glutathione trlpeptide  (oxidized plus reduced)/mg protein 
*" Mean ~  SEM, Number of experiments is in parentheses. 
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Flo.  3.  Effect of BCNU and aminotriazole on sensitivity of P388 (--), P815 (---) and J744 cells 
(- • -) to lysis  by fluxes  of H202. ~ZCr-release  was measured from the tumor cells  after 4.5-h incubation 
with dilutions of glucose oxidase. Before assay, the cells were treated with vehicle alone (veh, O) or 
100 #g/ml BCNU for 10 min (©), or incubated with 25 or 50 mM aminotriazole (AT, A) for 45-60 
rain before and then throughout the assay. Catalase (cat) (3,000 U/ml) abolished lysis in all cases, 
as shown for J774 (x). Points are means of triplicates. SEM averaged 2.0%. 
activity of any other enzyme tested (25). Accordingly, we measured GR in lysates of 
P815  mastocytoma after exposing the  intact cells to  the  drug for  10  min and then 
washing it out (Fig.  1). GR was 50% inhibited by 2.3 #g/ml (11/~M) BCNU and 95% 
inhibited by 100/~g/ml. Doses up to 300 ~g/ml did not affect the activity of GPO or 
catalase in the same cells (Fig.  1). Inactivation of GR by BCNU was rapid, being 50% 
complete in <30  s  and essentially complete in 5  min  (Fig.  2).  Similar results were 
obtained with P388 and TLX9 lymphomas (data not shown). 
Enhanced  Susceptibility  of  Tumor  Cells  to  Lysis  by  H202  After  Exposure  to  BCNU. 
Exposure of P815 mastocytoma cells to  100/~g/ml BCNU for I0 min was nontoxic, as 
judged by exclusion of trypan blue and release of 51Cr measured over a  period of 18 
h.  However. BCNU treatment made the tumor cells much more susceptible to lysis 
by small fluxes of H202.  For example, in the experiment illustrated in Fig. 3,  18.7 
times less glucose oxidase was required to cause 50% specific release of 5ZCr from P815 
cells  after  pulsing them  with  BCNU.  Similar results were  seen  with  all  six  of the NATHAN,  ARRICK,  MURRAY,  DESANTIS,  AND  COHN 
TABLE  II 
Effects of BCNU and Aminotriazole on Sensitivity of Tumor Cells to Lysis by Glucose Oxidase 
771 
Tumor 
TLX9  P388  YAC  P815  J774  NK 
Ratio of LDr,0 for glucose 
oxidase 
ControI*:BCNU$  6.4 +  4. I  (2)¶  21.3 ±  11.6 (4)  7.7 ±  4.0 (3)  5.5 ±  1.7 (9)  6.0 ±  2.6 (6)  4.3 ±  0.9 (2) 
Control:AT§  1.0 (1)  1.0 ±  0.2 (2)  ND**  1.0 ±  0.2 (2)  2.6 ±  0.8 (4)  2.6 (1) 
ControhBCNU +  AT  ND  4.5 (1)  ND  5.3 (1)  6.5 ±  1.6 (4)  7.4 (1) 
Spontaneous releasell 
Control  8A ±  1.3 (9)  8.8±0.4(7)  5.2:t:0.2(3)  8.4±0.6(14)  145±1.6(7)  13.9±3.3(4) 
BCNU  30.0±8.0(2)  25.8 ±  5.5 (4)  16.2 +  4.7 (3)  12.2  :t: 0.7 (9)  16.7±0.7(6)  11.8±1.8(2) 
AT  9.9 (1)  8.0 ±  2.7 (2)  ND  87:1:1.4  (2)  14.6 ±  1.7 (4)  9.9 ±  (1) 
BCNU +  AT  ND  28.7 (1)  NI)  14.5 (I)  17.0 ±  1.3 (4)  13.8 (I) 
* Tumor ceils were treated for l0 rain with 0.09%  ethanol in MEM-I% HS and then washed. 
:[: Tumor cells were treated for 10 mln with 100 #g/ml BCNU in 0.09% ethanol in MEM-1% HS. 
§ Tumor cells treated for 45-60 rain with 2.5 or 50 mM aminotriazole (AT); with the same concentration ofaminotriazole present during the 
assay. 
[I Percent release  of StCr from 4 X  10' tumor cells after 4.5 h  in 0.2 ml MEM-5% HS without glucose oxidase, 
¶ Mean :1: SEM, Number of experiments is in parentheses. 
** Not done. 
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Fro. 4.  Time-course of recovery of GR activity and resistance to H202, after exposure of P815 cells 
to  100 #g/ml BCNU  for  10 min. The LDs0 of glucose oxidase for treated and control cells was 
determined at each time point from curves like those in Fig. 3. 
tumors, whether they were initially more sensitive or more resistant to H202 than was 
P815  (Fig.  3), and whether or not BCNU  elevated their spontaneous release of 51Cr 
(Table  II).  Lysis of the BCNU-treated  tumors by glucose oxidase  was  abolished by 
catalase (Fig.  3). Results of all 26 such experiments are summarized in Table II. 
The  temporal  association  between  inhibition  of  GR  by  BCNU  and  enhanced 
sensitivity to  H202  is  seen  in  Fig.  4.  Both  functions recovered  in  a  linear  fashion, 
reaching pretreatment  values by 21-23 h. 
The effect  of the  concentration  of BCNU  on  H202  sensitivity was  evaluated  by 772  TUMOR  CELL  ANTI-OXIDANT  DEFENSES 
both ~*Cr release  and  dye exclusion  (Fig.  5).  Over  the range  from  3  to  100 #g/ml 
BCNU, the effect of the drug on GR (Fig. 1) paralleled its effect on peroxide sensitivity 
(Fig. 5 A). At 300/~g/ml  BCNU, an artifact was introduced into the 51Cr assay such 
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exposed to  the indicated concentrations of BCNU  for  10  min. The LDs0  of glucose oxidase for 
untreated and control cells were determined as in Fig. 3 (B) Trypan blue exlusion by P815 cells was 
tested after 10 rain of exposure of the cells to vehicle alone (0-..Q),  100 #g/ml BCNU (O---C)), or 
300 #g/ml BCNU (A--Z~), followed by 5 h  of incubation with different concentrations of glucose 
oxidase under the same conditions as in  (A).  100 #g/ml  BCNU decreased the LDs0  for glucose 
oxidase by a factor of 4.3, as measured by trypan blue exclusion, and by a factor of 4.7 as measured 
by 5~Cr release in the same experiment. 
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Fzc.  6.  Effect of BCNU on lysis  of P388 cells by PMA-stimulated peritoneal cells. (Q)  vehicle- 
treated P388.  (O)  P388 exposed to 100 ~g/ml BCNU for 10 min. (A) Lysis by glucose oxidase. (B- 
D) Lysis by peritoneal cells in the presence of 100 ng/ml PMA. (B) BCG-activated maerophages. 
(C) thioglycollate broth-elicited macrophages. (D)  resident macrophages. SEM averaged 2.7%. NATHAN, ARRICK,  MURRAY,  DESANTIS,  AND  COHN  773 
that the release of radiolabel underrepresented the degree of cell lysis. It should be 
noted that  at  100 #g/ml  BCNU,  the results of the 51Cr-release  assay and the dye 
exclusion test agreed closely (Fig. 5 B). This dose was used in all subsequent experi- 
ments. 
Enhancement of PMA-dependent, Macrophage-mediated Cytotoxicity by BCNU.  We next 
examined  the  sensitivity of BCNU-treated  tumor  cells  to  injury by  macrophage 
populations. The agent used to induce the release of oxygen intermediates in this case 
was PMA. Fig. 6 shows the results with BCG-activated (Fig. 6 B), thioglycollate broth- 
elicited  (Fig.  6C),  and  resident  macrophages  (Fig.  6D).  After exposure  of P388 
lymphoma cells to  BCNU,  the  BCG-activated  macrophages became  33-fold more 
effective in their lytic activity. Of considerable interest was the cytolytic capacity of 
both  resident  and  thioglycollate broth-elicited  macrophages  against  the  BCNU- 
treated target. The same macrophage populations were incapable of lysing untreated 
P388 cells. The cytolytic efficiency of each macrophage population can be compared 
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FIo.  7.  Effect of BCNU on lysis of P815 cells by BCG-activated macrophages in the presence of 
(A)  PMA,  100  ng/ml or  (B)  anti-tumor alloantiserum. (0)  P815 cells treated  with vehicle alone. 
(O)  P815 treated with  100 gg/ml BCNU for 10 rain. SEM averaged 1.3%. 
TABLE  III 
Effect of BCNU on Antibody-dependent, Macrophage-mediated Lysis of P815 
Exp.  E:T ratio* 
Specific release of StCr 
Vehicle:]:  BCNU§ 
Specific 
release 
(BeNU/ 
vehicle) 
1  16  20.2 ±  0.711  49.8 +  2.7  2.47 
2  15  28.2 :t:: 0.7  41.3 ±  1.1  1.46 
3  23  37.9 ±  1.6  74.7 ±  1.7  1+97 
4  41  26.4 ±  1.4  62.7 ±  0.3  2.38 
5  20  12.6 ±  0.5  31.7 ±  2.1  2.52 
6  29  43.1 ±  2.2  58.5 ±  4.4  1.36 
* Various numbers of macrophages from BCG-treated mice were incubated for 4.5 h 
with 2 ×  104 S]Cr-labeled P815 cells that had been exposed to alloantiserum. 
:~ Target cells were treated for 10 rain with 0.09% ethanol in MEM-1% HS. 
§ Target cells were treated  for  10 min with  100 p.g/ml BCNU in 0.09% ethanol  in 
MEM-1% HS. 
I[ Means ±  SEM for triplicates. 774  TUMOR CELL ANTI-OXIDANT DEFENSES 
with  the lysis by enzymatically generated  H202 in  the same experiment  (Fig.  6A). 
The observed degrees of cell-mediated lysis would be expected if the BCG-activated 
macrophages released  5.9  nmol H202/10 s cells per 5  min, the thioglycollate broth- 
elicited cells released  1.1  nmol, and the resident cells released 0.14 nmol. These rates 
agree closely with those previously observed (10,  11). 
Less  striking  but  still  pronounced  effects were  noted  using  P815,  a  tumor  with 
greater intrinsic resistance to peroxide (Fig. 7 A). In three experiments, BCG-activated 
macrophages were 2.9 -+ 0.1  times more active against the BCNU-treated tumor cells 
at any given effector:target ratio. 
Enhancement of Antibody-dependent, Macrophage-mediated Cytotoxicity by  BCNU.  Acti- 
vated macrophages bind and lyse tumor targets coated with specific antibody (7). At 
least 62% of this activity was oxygen-dependent (8).  The ability of BCNU to modify 
the lysis of alloantiserum-coated P815 cells is illustrated in Fig.  7 B and Table III. In 
six  such  experiments,  BCNU  treatment  of the  target  enhanced  cytolysis by BCG- 
activated  macrophages  by  a  factor  of 2.0  +  0.2.  The  increased  efficiency  of the 
reaction against BCNU-treated tumor cells was also manifest as an eightfold reduction 
in the amount of antibody required to achieve the same degree of lysis (Fig. 8). 
Specificity of Action of BCNU.  BCNU  did  not  simply  make  tumor  cells  more 
susceptible  to  any  form  of humoral  or  cell-mediated  injury.  Thus,  antibody  plus 
complement  did  not  lyse  BCNU-treated  target  cells  any more readily  than  native 
target cells (Table IV). Likewise, the lysis of tumor cells by allosensitized T  cells was 
not affected by BCNU (Table IV). This was true even when BCNU itself was slightly 
toxic to certain of the tumor cells, as judged by elevation in their spontaneous release 
of 51Cr (Table II). Finally, of 11  anti-neoplastic agents, only BCNU sensitized tumor 
cells to lysis by H202 under the conditions tested. The following drugs were incubated 
with TLX9 or P815 cells at 0.47 mM for 10-30 min, and gave the indicated ratio of 
half lethal doses (LDso)  of glucose oxidase for control cells:drug treated ceils: CCNU 
(1.13),  methyl-CCNU  (0.91),  chlorambucil  (1.26),  melphalan  (0.99),  5-fluorouracil 
(0.87), Ara-C (0.72), methotrexate (0.64), doxorubicin hydrochloride (0,61), mitomy- 
cin C  (0.88), and cis-diaminedichloroplatinum  (0.76). 
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TABLE  IV 
Lack of Effect of BCNU on Susceptibility of Tumor Cells to Lysis by Antibody Plus 
Complement or by Allosensitized Spleen Cells 
775 
Tumor  Lytic agents 
Specific release of SlCr from 
tumors treated with 
Vehicle*  BCNU:[: 
TLX9 
P815 
TLX9 
Antibody§ 
1:100 +  C'II  76.0 ±  0.3¶  59.0 ±  4.3 
1:300 +  C'  37.3 ±  1.4  27.2 ±  3.9 
1:t,1300 +  C'  9.8 +  1.5  5.1 +  0.7 
C57BL/6 anti-CD2Fl spleen cells** 
E:T, 50  70.6 ±  7.8  81.2 ±  2.4 
E:T, 15  45.5 +  2.5  45.3 ±  0.8 
E:T, 5  20.1 ±  1.1  18.6 +  1.l 
E:T, 1.5  9.2 ±  1.0  8.l +  0.9 
E:T, 0.15  1.2 :tz 0.6  1.2 +  0.9 
CD2FI anti-C57BL/6 spleen cells** 
E:T, 50  93.8 -4- 2.6  88.1 ± 9.8 
E:T, 15  83.0 +  6.3  69.2 ±  4.9 
E:T, 5  57.3 ±  2.1  40.5 ±  4.9 
E:T, 1.5  18.2 +  2.2  t6.4 +  2.7 
E:T, 0.15  2.8 ± 0.6  -1.2 +  2.0 
* Tumor  cells  were exposed  to  0.09% ethanol  in  MEM-I%  HS  for  30  min  (lst 
experiment) or 10 min (2nd and 3rd experiments). 
~: Tumor ceils exposed  to 100/zg/m[ BCNU in vehicle as in footnote * above. 
§ Rabbit anti-mouse lymphocyte antiserum, heat-inactivated. 
II Fresh normal rabbit serum, 1:20. Specific release with complement (C') but without 
antibody was 6.0% for vehicle-treated cells and  1.9% after BCNU. 
¶ Means ±  SEM for triplicates. 
** Mice were immunized  in  vivo and  their spleen cells  boosted  twice in  vitro as 
described  in  Materials and  Methods.  P815  shares  the major histocompatibility 
antigens of CD2FI mice. TLX9 arose in a C57BL/6 mouse. Effector cells were also 
tested  at  each  effector:target  (E:T)  ratio  against  the  homologous  target,  both 
vehicle-treated and BCNU-treated; specific release ranged from -15% to 3.2%. 
Inhibition  of GPO by Dietary  Deprivation  of Selenium.  Another  method  of interrupting 
the  glutathione  redox  cycle,  in  the  absence  of drugs,  was  to  take  advantage  of the 
selenium  dependence  of GPO  (26).  Mice were fed a  selenium-deficient  diet  for 4  wk 
and  were  then  employed  as hosts  for the aseites  form of TLX9  lymphoma.  After  10 
wk of passage in selenium-depleted mice, the GPO  activity of TLX9  cells was reduced 
85%  (Fig.  9B),  with  no  effect  on  tumor  cell  GR  (Fig.  9C),  catalase  (Fig.  9D),  or 
glutathione  (data not shown). The selenium-deficient tumor cells were threefold more 
sensitive  to  lysis  by  H202  than  the  controls  (Fig.  9A).  In  three  such  experiments, 
s~nsitivity  of TLX9  cells  from  selenium-deficient  mice  increased  3.4  +  0.6  times 
compared  with  TLX9  cells  from  selenium-repleted  mice.  Similar  results  were  seen 
with P815  cells. 
PMA-triggered  cytolysis by BCG-activated  macrophages  and  by granulocytes  was 
markedly  augmented  against  selenium-deficient  TLX9  cells,  compared  with  tumor 
cells from selenium-repteted  mice (Fig.  10). 
Inhibition  of Catalase.  The  catalase  activity ofJ774  was  inhibited  100%  by 60 min 776  TUMOR  CELL ANTI-OXIDANT DEFENSES 
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F~c.  10.  PMA-dependent lysis of TLX9 cells from selenium-deficient (O) and selenium-repleted 
mice (0) by (A) BCG-activated macrophages and (B) peritoneal granulocytes. SEM averaged 4.5%. 
incubation  in  50  mM aminotriazole at  37°C.  Catalase  in  P388  and  P815  cells was 
inhibited  90%  by  incubation  in  25  mM  aminotriazole  for  45  min.  Inhibition  of 
catalase  in  the  latter  tumors  was  probably  increased  even  more  by  the  further 
inclusion of aminotriazole in the cytolysis assay itself, because aminotriazole inhibits 
catalase more effectively in the presence of H202 (27). Used as described, aminotriazole 
did not augment the lysis of TLX9,  P388, or P815 cells by enzymatically generated 
H202 (Table II and Fig.  3), by reagent  H202 added as a  bolus (data not shown), or 
by BCG-activated macrophages in the presence of PMA or anti-tumor antibody (data 
not  shown).  The sensitivity  ofJ774  histiocytoma and  NK  lymphoma to  H202 was 
enhanced to a modest degree by aminotriazole in some but not all experiments (Table 
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Discussion 
If the biochemical basis of cytotoxicity is known in a given experimental setting, it 
becomes feasible to hypothesize the pathways the target cell might employ to reduce 
or escape injury. If such pathways are identified, means can be sought to block them. 
Reactive oxygen intermediates, including H202, appear to be prominently involved 
in the cytotoxicity of activated macrophages in the presence of PMA (6) or anti-tumor 
antibody  (8).  Tumor cells are likely to possess several mechanisms,  enzymatic and 
nonenzymatic,  for disposal  of H202.  We  focused on  three  enzymes within  tumor 
cells--catalase, GR, and GPO--and the substrate, glutathione. 
Of  these  four  variables,  only  the  content  of  glutathione  correlated  with  the 
susceptibility  of six  different  tumors  to  lysis  by  fluxes of H202.  More  important, 
inhibition of the cyclic oxidoreduction of glutathione markedly sensitized each of the 
tumor lines to oxidant injury. 
Novel approaches were necessary to establish this point. Specific inhibitors of GR 
or  GPO  are  not  available.  Familial,  congenital,  or  acquired  deficiencies of these 
enzymes have been identified in human leukocytes or erythrocytes (28), but not, to 
our knowledge, in tumor cells from man or mouse. Agents are available that rapidly 
oxidize glutathione  to its  disulfide in  intact  cells  (29), but  their effect is  transient, 
because the cells reduce the disulfide back to glutathione (29, 30). In our hands, one 
such agent, diazenedicarboxylic acid bis-(N,N-dimethylamide), or diamide,  had  no 
effect on  peroxide-mediated lysis  of tumor  cells  (data  not  shown).  Therefore, we 
explored four separate ways to interrupt the glutathione redox cycle over a period of 
hours (Fig.  11). 
First, we inactivated GR by pulsing the tumor cells with BCNU. This approach 
was based on the work of Frischer and Ahmad (25) and Babson and Reed (31), who 
demonstrated inhibition of GR in nonmalignant human and murine cells by BCNU. 
Frischer and Ahmad observed no effect of BCNU on 17 other enzymes in erythrocytes, 
including those of the hexose monophosphate shunt and the Embden-Meyerhof path 
(25). We found that BCNU inhibition of GR in intact tumor cells was potent (dose 
causing 50% inhibition [IDs0]:  11 #M) and rapid (50% inhibition in 30 s). Moreover, 
the action of BCNU was relatively specific, in that catalase and GPO were unaffected; 
the tumor cells were not made more susceptible to lysis by antibody and complement, 
nor by allosensitized T  cells; and  10 other anti-neoplastic agents, including alkylating 
glu  ~  cys  electrophile 
~'GCS~'~gly  /~  thioether 
NADPy  GSH  _  H  2  0  2 
NADPH~GSSG  ~  21120 
FIG.  1  1.  The oxidation-reduction cycle of glutathione and several related reactions.  The enzymes 
shown are: GPO; GR; ~'-GCS, y-glutamyl-cysteine synthetase;  GS, glutathione synthetase;  GST, 
glutathione S-transferase.  The substrates  include: GSH, reduced glutathione; GSSG, glutathione 
disulfide;  glu, glutamate; cys, cysteine;  gly, glycine. 778  TUMOR CELL ANTI-OXIDANT DEFENSES 
compounds,  were  without  similar  effects.  BCNU-induced  inhibition  of  GR  and 
sensitization of tumor cells to oxidative injury shared the same dose-response curve, 
and were reversible with the same time-course. 
When GR was inactivated within tumor cells, the tumor cells could be injured by 
fluxes of H202 which were otherwise inconsequential; they could be killed by numbers 
of activated macrophages or granulocytes which were otherwise insufficient; and they 
could be lysed by nonactivated macrophages, which were otherwise ineffective. They 
could be killed by activated macrophages in the presence of anti-tumor antibody in 
concentrations which were otherwise too dilute. 
As a second, independent way of interfering with the redox cycle of glutathione, we 
inhibited  GPO,  a  selenoenzymc  (26),  by passage of the  tumor cells  in  mice  fed  a 
selenium-deficient  diet.  This  approach  was  based  on  the  work  of  a  number  of 
laboratories, in which leukocyte (32-34)  or cardiac (35)  GPO was inhibited through 
selenium deprivation. Previous attempts to deplete tumor cells of selenium have been 
disappointing,  perhaps because of the  ability of the  tumor to command the  host's 
selenium  reserves  (36).  Nonetheless,  with  time, we observed a  selective decrease  in 
activity of GPO in lymphoma and mastocytoma cells, with no effect on GR, catalase, 
or glutathione.  The GPO-deficient tumor cells were much more sensitive to lysis by 
enzymatically generated HzOz and by PMA-triggered granulocytes and macrophages. 
This effect could be prevented by making the diet replete with selenium, and it could 
be reversed by incubating the cells in serum-containing medium (data not shown). 
Oxidative injury of tumor cells was augmented less by selenium deprivation than 
by  treatment  with  BCNU.  Two  factors  may  have  contributed  to  this  difference. 
BCNU  inhibited  GR  almost  completely, whereas  selenium  deprivation  resulted  in 
only  an  85%  reduction  in  the  activity  of  GPO.  Furthermore,  H202  can  oxidize 
glutathione nonenzymatically, but the nonenzymatic reduction of glutathione disul- 
fide  is extremely slow.  Thus,  the  glutathione  redox  cycle should  be blocked  more 
effectively by inhibition of GR than by inhibition of GPO. 
As  a  third  way  to  interrupt  the  glutathione  cycle,  we  used  an  inhibitor  of y- 
glutamyl-cysteine synthetase to block glutathione synthesis (37)  (Fig.  11). As a fourth 
method,  we  depleted  tumor  cell  glutathione  through  thioether  formation  with  a 
halogenated hydrocarbon, as catalyzed by endogenous glutathione S-transferase (38) 
(Fig.  11).  These last  2  approaches will  be described  elsewhere  (B.  A.  Arrick,  C.  F. 
Nathan, Z. A. Cohn, and O. W. Griffith, manuscript  in preparation).  The diversity 
of these four pharmacologic and dietary manipulations, all giving the same end result, 
strongly supports  the  interpretation  that  they each sensitize tumor cells to oxidant 
injury by interfering with the redox cycle of glutathione. 
Catalase activity varied 56-fold in the six tumors studied.  However, there was no 
correlation between the specific activity of catalase and the native resistance of tumor 
cells  to  peroxide-mediated  lysis.  Inhibition  of catalase  with  aminotriazole  did  not 
augment  lysis of TLX9,  P388  or  P815  cells by activated  macrophages or by enzy- 
matically generated  H2Oz. With  two other tumors,  inhibition  of catalase enhanced 
peroxide-mediated lysis to a modest degree. It is of interest that the latter two tumors 
were  those  with  the  highest  and  lowest  levels of catalase.  In  another  macrophage 
effector function,  catalase appears to be of more consequence:  the ability of macro- 
phages to kill the intracellular parasite Toxoplasma gondii is regulated  in part by the 
catalase activity of both the macrophage and the parasite (39). NATHAN, ARRICK, MURRAY, DESANTIS, AND COHN  779 
Additional  anti-oxidant  defenses undoubtedly exist  in  tumor cells, besides  those 
identified here. This is illustrated by the finding that inhibition of GR, GPO, and/or 
catatase  in  tumors  of differing sensitivities  to  HeO2  did  not  render them  equally 
sensitive. Other substances which might serve as anti-oxidants in tumor ceils include 
olher peroxidases, superoxide dismutase, vitamins C and E, free and protein cysteine, 
and unsaturated fatty acids. 
The work described here may shed some light on the pulmonary toxicity which 
afflicts up to 20% of patients who receive large cumulative doses of BCNU  (40,  41). 
The high oxygen tension in the pulmonary alveolus, compared with the rest of the 
body,  may predispose the  lung  to oxygen toxicity when  anti-oxidant  defenses are 
impaired. Alveolar macrophages, in particular, rely heavily on the glutathione redox 
cycle for disposal  of HzOz  (42).  It  is  known  that  familial  GR  deficiency leads  to 
oxidative autotoxicity in monocytes and granutocytes (20). Therefore, the pulmonary 
toxicity of BCNU may stem in part  from its inactivation of GR in alveolar macro- 
phages  and  other  pneumocytes,  with  oxidative  injury  initiating  an  inflammatory 
response. We are currently studying the effect of BCNU on macrophages. 
BCNU treatment of target cells had no effect on cytotoxicity mediated by T  cells. 
This observation argues against an oxidative mechanism in that process, but does not 
exclude one. Tumor cell defenses might not be rate-limiting in T  cell-mediated lysis. 
An  injury might  be delivered at  a  site not  readily repaired, or by an oxidant  not 
efficiently scavenged, by the cytosolic glutathione redox cycle. 
It should also be noted that  the procedures used here for decreasing the levels or 
the oxidoreduction of glutathione are all reversible. As such, they are not well suited 
to the study of spontaneous macrophage-mediated cytotoxicity, which is a relatively 
slow process in vitro. 
However,  the  findings  reported  here  do  argue  strongly  for  the  involvement  of 
reactive  oxygen  intermediates,  especially  H202,  in  the  cytotoxicity  of activated 
macrophages in the presence of PMA (6) or anti-tumor antibody (8). The ability of 
the tumor cell to catabolize H20~ appears to be a limiting factor in its susceptibility 
to  lysis in  both settings.  It  is  possible  that  interference with  glutathione  reduction 
could also affect antibody-dependent, cell-mediated cytotoxicity in other ways, such 
as by promoting the capping of antigen-antibody complexes on the tumor cell surface 
(30). 
These studies raise the possibility that therapeutic strategies involving macrophage- 
mediated, antibody-dependent cytolysis, or other forms of oxidant injury, might be 
augmented  by  the  appropriate  use  of specific  chemotherapeutic  agents  acting  to 
inhibit tumor cell anti-oxidant defense. 
Summary 
The basis of resistance to oxidative injury was studied in six murine tumor cell lines 
that differed 54-fold in their resistance to enzymatically generated H202. The tumors 
varied 56.7-fold in their specific activity ofcatalase, 5.3-fold in glutathione peroxidase 
(GPO),  3.3-fold in  glutathione reductase  (GR), and  2.7-fold in glutathione.  There 
was no correlation among the levels of the three enzymes, and tumor cell resistance to 
lysis  by H202.  However, the logarithm of the flux of H20~ necessary to cause 50% 
iysis of the tumor cells correlated with their content of glutathione  (r =  0.91). The 
protective role of glutathione was analyzed by blocking GR and GPO, the catalysts 780  TUMOR CELL ANTI-OXIDANT DEFENSES 
of the  glutathione  redox cycle. This  was  facilitated  by the  demonstration  that  the 
anti-neoplastic  agent  1,3-bis-(2-chloroethyl)-l-nitrosourea  (BCNU)  was a  potent  in- 
hibitor of GR  in  intact  tumor cells.  BCNU  inactivated  tumor cell  GR with  a  50% 
inhibitory dose of 11/~M and a  tl/2 of inhibition of 30 s. Complete inhibition of GR 
was attained with no effect on GPO or catalase. Tumor cells whose GR was inactivated 
by BCNU could be lysed by fluxes of H202 to which they were otherwise completely 
resistant. They could be killed by phorbol myristate acetate (PMA)-stimulated, bacille 
Calmette-Gu~rin-activated  macrophages  in  numbers  which  were  otherwise  insuffi- 
cient,  and by nonactivated  macrophages,  which otherwise  were ineffective.  BCNU- 
treated  target  cells  were  also  much  more  sensitive  to  antibody-dependent,  macro- 
phage-mediated  cytolysis.  However,  such  tumor  cells  were  no  more  sensitive  than 
controls to lysis by alloreactive T  cells or by antibody plus complement. 
Next,  we deprived tumor cells of selenium  by passage in selenium-deficient  mice. 
GPO was inhibited  85% in such cells, with no effect on GR or catalase.  Tumor cells 
with reduced GPO activity were markedly sensitized to lysis by small fluxes of H202 
or by PMA-stimulated macrophages or granulocytes. In contrast, inhibition ofcatalase 
with  aminotriazole  had  no  effect  on  the  sensitivity  of three  tumors  to  peroxide- 
mediated lysis, and had modest effects with two others. 
Thus, the oxidation-reduction cycle of glutathione serves as one of the major defense 
mechanisms of tumor cells against three related forms of oxidant injury: lysis by fluxes 
of H202,  by  PMA-triggered  macrophages,  and  by macrophages  in  the  presence  of 
anti-tumor antibody. 
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